Cargando…
Transplantation of HCV Viremic Livers into HCV Viremic Recipients Followed by Direct-acting Antiviral Therapy
Background and Aims: Hepatitis C virus (HCV)-infected organs are underutilized. We aimed to assess the safety and efficacy of direct-acting antiviral agents (DAAs) therapy in HCV viremic patients who are transplanted with a liver from a HCV viremic donor. Methods: We conducted a retrospective study,...
Autores principales: | Kapila, Nikhil, Khalloufi, Kawtar Al, Flocco, Gianina, Menon, K.V. Narayanan, Lindenmeyer, Christina, Reino, Diego, Vanatta, Jason M., Ebaid, Samer, Tzakis, Andreas, Zervos, Xaralambos Bobby |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
XIA & HE Publishing Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609846/ https://www.ncbi.nlm.nih.gov/pubmed/31293911 http://dx.doi.org/10.14218/JCTH.2019.00014 |
Ejemplares similares
-
Utilization of HCV viremic donors in kidney transplantation: a chance or a threat?
por: Czarnecka, Paulina, et al.
Publicado: (2022) -
Efficacy and Safety of Direct-Acting Antivirals in Kidney Transplantation From HCV-Viremic Donors to Negative Recipients: A Meta-Analysis
por: Feng, Zepei, et al.
Publicado: (2022) -
Incorporating Patients’ Values and Preferences Into Decision Making About Transplantation of HCV-Naïve Recipients With Kidneys From HCV-Viremic Donors: A Feasibility Study
por: Eckman, Mark H., et al.
Publicado: (2021) -
Variation analysis of six HCV viral load assays using low viremic HCV samples in the range of the clinical decision points for HCV protease inhibitors
por: Wiesmann, F., et al.
Publicado: (2014) -
Outcome of Kidney Transplants from Viremic and Non-Viremic Hepatitis C Virus Positive Donors into Negative Recipients: Results of the Spanish Registry
por: Franco, Antonio, et al.
Publicado: (2023)